Exploring Diabetes and Mental Health Issues

Exploring Diabetes and Mental Health Issues

Living with a chronic disease can take a toll on one’s mental health, so how can healthcare providers best support those living with diabetes?

Our host, Dr. Ronald Goldenberg, takes a deeper look into this topic with Dr. Michael Vallis, a Health Psychologist and Health Behaviour Change Consultant based in Halifax, and an Associate Professor in Family Medicine at Dalhousie University. He has authored chapters in the recent 2013 and 2018 Diabetes Canada Clinical Practice Guidelines on Diabetes and Mental Health.

This episode discusses the common mental health issues associated with diabetes, with a particular focus on diabetes distress, psychological insulin resistance, and the fear of hypoglycemia. Our experts expand on the topics of what drives these challenges, how to recognize them in people living with diabetes, and the recent advances in diabetes management that allow individuals to overcome these barriers. They also discuss how to address these issues in a collaborative manner for more effective diabetes care and greater overall health outcomes.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Goldenberg:

  • Direct financial relationship including receipt of honoraria: Abbott, Agora, Amgen, Antibody, AstraZeneca, Bayer, Boehringer Ingelheim, CCRN, CMSKTRG, Eli Lilly, EOCI, HIT Global, HLS, Inceptus, Janssen, LiV, Master Clinician Alliance, MD Briefcase, Merck, Mylan, Novo Nordisk, Sanofi, Script Medical, Servier, STA, Takeda, Toronto Knowledge Translation Working Group, Unik, Valeant. Membership on advisory boards or speaker’s bureau: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS, Janssen, Merck, Novo Nordisk, Sanofi. Funded grants, research or clinical trials: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi.

Dr. Vallis:

  • Membership on advisory boards or speaker’s bureau: Novo Nordisk, Abbvie, Bausch, Boehringer Ingelheim, Sanofi, Abbott, Lifescan, Merck. Funded grants, research or clinical trials: Novo Nordisk, Bausch, Abbott.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(26)

Exploring Second-Generation Basal Insulin Analogues 

Exploring Second-Generation Basal Insulin Analogues 

Do second-generation basal insulin analogues really offer any advantages over their first-generation counterparts?  Our host, Dr. Ronald Goldenberg, takes a deeper look into this topic with Dr. Alice ...

15 Nov 202213min

Navigating the Diabetes Canada Algorithm for Pharmacologic Glycemic Management of Type 2 Diabetes

Navigating the Diabetes Canada Algorithm for Pharmacologic Glycemic Management of Type 2 Diabetes

Diabetes Canada updated their recommendations for the pharmacologic glycemic management of type 2 diabetes in adults in 2020, but how can clinicians interpret and implement these guidelines in their e...

15 Nov 202228min

Navigating Ramadan with Diabetes

Navigating Ramadan with Diabetes

How can healthcare providers best guide Muslims living with diabetes to safely observe fasting during Ramadan?Our host, Dr. Ronald Goldenberg, takes a deeper look into this topic with Dr. Ally Prebtan...

1 Nov 202214min

Managing Diabetes in Pregnancy  

Managing Diabetes in Pregnancy  

How do we approach diabetes management during pregnancy?Our host, Dr. Ronald Goldenberg, takes a deeper look into this topic with Dr. Denice Feig, an Endocrinologist, diabetes researcher, and champion...

1 Nov 202210min

Examining Diabetes and Renal Impairment 

Examining Diabetes and Renal Impairment 

Did you know that people with type 2 diabetes having chronic kidney disease are at an increased risk of hypoglycemia?Our host, Dr. Ronald Goldenberg, takes a deeper look into this topic with Dr. Alice...

15 Okt 202210min

Recent Evidence for Fixed-Ratio Combinations of Basal Insulin and GLP-1 RA vs. Basal-Bolus Insulin in T2D: Updates from ADA 2022

Recent Evidence for Fixed-Ratio Combinations of Basal Insulin and GLP-1 RA vs. Basal-Bolus Insulin in T2D: Updates from ADA 2022

Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) have demonstrated maintenance of HbA1c efficacy, less hypoglycemia, and weight loss compared to basal-...

1 Okt 202214min

Practical Tips to Interpreting Continuous Glucose Monitoring Metrics

Practical Tips to Interpreting Continuous Glucose Monitoring Metrics

With newer technologies being used to monitor blood glucose levels, how can we use data from continuous glucose monitoring (CGM) to inform the day-to-day management of diabetes?Our host, Dr. Ronald Go...

1 Okt 202221min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
liberal-halvtime
jss
rss-zahid-ali-hjelper-deg
sinnsyn
forskningno
villmarksliv
rekommandert
rss-overskuddsliv
rss-paradigmepodden
vett-og-vitenskap-med-gaute-einevoll
nordnorsk-historie
tidlose-historier
dekodet-2
rss-inn-til-kjernen-med-sunniva-rose
fjellsportpodden
kvinnehelsepodden
diagnose
rss-nysgjerrige-norge